Alpa Laboratories Peer Comparison

NSE: ALPA | BSE: 532878

₹61.50

₹0.05 (0.08%)

As on 27-Aug-2026 13:19IST

Market cap

₹130 Cr

Revenue (TTM)

₹111 Cr

P/E Ratio

29.8

P/B Ratio

0.7

Div. Yield

0 %

Edit

	Alpa Laboratories	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Market cap (₹ Cr)	130	21,894	19,021	17,760	18,168
Revenue (₹ Cr)	111	2,570	2,287	2,432	3,230
Net Profit (₹ Cr)	4.38	735.15	678.07	169.62	666.92
Net Margin (%)	3.64	26.88	28.10	6.90	20.60
RoE (%)	2.37	19.16	19.73	20.76	18.75
Price to Earnings	29.80	29.78	28.59	104.70	28.21
Price-To-Book	0.70	4.97	5.05	19.64	4.49

Income Statement (₹ Cr)

	Alpa Laboratories	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Operating Revenue	110.63	2,569.77	2,287.33	2,432.06	3,229.67
Total Income	120.21	2,735.39	2,413.29	2,458.54	3,237.12
Total Expenditure	111.72	1,628.14	1,490.75	2,202.20	2,090.06
EBITDA	-1.09	941.63	796.58	229.86	1,139.61
Depreciation	2.26	57.58	78.10	17.24	281.06
EBIT	-3.35	884.05	718.48	212.62	858.55
Interest	0.32	7.69	0.88	5.72	190.64
Other Income	9.58	165.62	125.96	26.48	7.45
Exceptional Items	0.00	-49.16	0.00	-5.13	-17.24
Profit before Tax	5.91	992.82	843.56	228.25	658.12
Provision for Tax	1.53	257.67	165.49	58.63	-8.80
Profit after Tax	4.38	735.15	678.07	169.62	666.92

	Alpa Laboratories	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Shareholder's Funds	186.28	4,202.90	3,586.42	872.79	3,902.67
Minority Interest	0.00	0.00	-12.71	0.00	-21.81
Non-Current Liabilities	3.34	91.50	28.74	134.50	1,392.75
Current Liabilities	52.53	627.48	385.94	981.81	2,077.10
Total Liabilities	222.63	4,911.11	3,207.85	1,879.19	6,862.28

	Alpa Laboratories	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Non-Current Assets	26.78	770.28	1,291.22	42.47	5,617.77
Current Assets	210.90	3,803.22	2,585.66	1,739.93	1,539.85
Total Assets	222.63	4,911.11	3,207.85	1,879.19	6,862.28
Total Debt*	0.03	2.50	0.55	0.00	2,421.66
Net Current Assets	158.37	3,175.74	2,199.72	758.12	-537.25
Contingent Liabilities	6.65	363.79	0.64	98.41	64.29

	Alpa Laboratories	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Cash From Operating Activities	18.32	659.75	432.37	65.36	1,065.01
Cash Flow from Investing Activities	-12.36	-71.34	-334.73	30.80	-79.97
Cash from Financing Activities	-5.44	-205.34	-38.32	-65.59	-881.32
Net Cash Inflow / Outflow	0.51	383.07	59.32	30.57	103.72

	Alpa Laboratories	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
ROCE (%)	15.76	26.21	26.22	21.29	13.59
ROE (%)	2.37	19.16	19.73	20.76	18.75
ROA (%)	1.88	14.95	18.69	9.67	9.26
EBIT Margin (%)	-3.03	34.40	31.41	8.74	26.58
Net Margin (%)	3.64	26.88	28.10	6.90	20.60
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Alpa Laboratories	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Revenue Growth (%)	0.46	10.69	15.01	31.10	9.59
EBIT Growth (%)	-235.67	24.14	18.45	-12.99	16.84
Net Profit Growth (%)	-83.31	-9.09	19.61	-7.49	62.68
EPS Growth (%)	-83.31	14.40	17.73	-18.33	67.41
Book Value Growth (%)	12.85	17.30	23.77	7.70	10.19

	Alpa Laboratories	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Price / Earnings	29.66	28.45	28.78	103.08	27.49
Price / Book Value	0.69	4.98	5.08	19.78	4.48
Dividend Yield (%)	0.00	1.56	0.16	0.50	0.55
EV/EBITDA	-15.71	20.01	22.90	75.87	17.84
Market Cap (₹ Cr)	219.08	18,318.10	15,219.80	21,515.93	19,292.77

	Alpa Laboratories	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Debt to Equity	0.00	0.00	0.00	0.00	0.24
Short term debt to equity ratio	0.00	0.00	0.00	--	0.14
Current Ratio	4.01	6.06	6.70	1.77	0.74
Quick Ratio	3.76	5.31	5.59	0.73	0.53
Interest Coverage	19.47	130.11	959.59	40.90	4.45

	Alpa Laboratories	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Debtors to sales (%)	36.91	7.07	36.10	8.79	21.07
Asset Turnover	0.48	0.52	0.63	1.39	0.45
Receivable days	142.78	29.10	110.70	35.81	54.07
Inventory Days	50.81	69.53	65.86	82.25	32.16
Payable days	79.22	76.77	105.88	124.39	140.91
Cash Conversion Cycle	114.37	21.86	70.68	-6.33	-54.68

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.